1. ¹Department of Pathology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
2. ²Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
3. ³Laboratory of Biochemistry, Department of Biology, University of Konstanz, Constance, Germany
4. ⁴Translational Research Laboratory, Institut Catala d'Oncologia, Barcelona, Spain

Correspondence: Daniëlle A. M. Heideman, Department of Pathology, VU University Medical Center, P.O. Box 7057s, 1007 MB Amsterdam, The Netherlands. Fax: +31 20 444 2964. E-mail: dam.heideman@vumc.nl

Received 1 March 2005; Revised 6 June 2005; Accepted 7 June 2005.

Abstract

Rationale in the development of novel treatment strategies for HPV-associated cancers is targeting on the basis of the presence of HPV in (pre)malignant cells. Here, we designed a new conditionally replicating adenovirus (CRAd) for selective and effective oncolytic replication in HPV-containing cells. As the backbone, we used the CRAd AdCB016, which replicates selectively in cells expressing HPV E6 and E7 proteins. To enhance its oncolytic potency, we armed AdCB016 with p53 variant mp53(268N), which is resistant to HPV E6-mediated degradation. The new CRAd AdCB016-mp53(268N) was analyzed for its lytic replication properties in cervical carcinoma cell lines, HPV-immortalized keratinocyte cell lines representing dysplastic cells, and primary human keratinocytes. AdCB016-mp53(268N) exhibited 10- to 1000-fold greater efficacy than AdCB016 on high-risk HPV-positive cervical carcinoma cells and HPV-immortalized keratinocytes. Importantly, infection with AdCB016-mp53(268N) did not affect primary nonmalignant human keratinocytes. This favorable efficacy and safety profile was confirmed in organotypic raft cultures. Our findings suggest that AdCB016-mp53(268N) is a promising new agent for treatment of HPV-associated human cancers.